CA
NZ
UK
AU
IND
US
Profusa, Inc. (NASDAQ:PFSA), a biosensor and diagnostics company, is working toward closing a transformativeAcquisitionwhile managing a distressedBalance Sheetand its Nasdaq listing requirements.
The company's request for a hearing before a Nasdaq Hearings Panel is a strategic move in its appeal process, offering an opportunity to contest the decision and seek to maintain its listing on Nasdaq. The timing of this request is critical as it occurs …
707 Cayman Holdings Limited is set to significantly expand its operations by entering the pharmaceutical sector through the proposed acquisition of Crucial Innovation Inc. The transaction is backed by $10.25 million in financing, primarily led by GeoNova Holdings. This financing is intended to facilitate …
This achievement initiates the formal regulatory process for CannEpil® as an investigational veterinary pharmaceutical aimed at managing cancer-related pain in companion animals. This milestone underscores the company's commitment to addressing a critical need in veterinary medicine, given the absence of FDA-approved therapies specifically for …
Merck & Co. Inc. (NYSE: MRK), which boasts a marketCapitalizationof approximately $371.7 billion and reported revenue of $65.01 billion, recently experienced a significant surge in its stock price. Shares climbed 12.6% to reach a record high of $152.20 on August 19, buoyed by the …
This strategic move is intended to bolster the company's leadership team as it progresses in its mission to develop innovative oral medications that target G protein-coupled receptors (GPCRs). Patni's extensive background in clinical development and regulatory affairs positions him to significantly influence the success …
Generate Biomedicines Inc has seen its stock price rise by over 20% as the expiration of its post-IPO lock-up period approaches. The surge in stock price indicates that investors are positioning themselves ahead of increased supply in the market. Market reactions of this nature …
Capricor Therapeutics stock has surged significantly following an upgrade by Oppenheimer, as investors reacted positively to recent developments that could affect the company's regulatory standing. This upward movement in stock price signifies a renewed optimism in Capricor’s potential, driven by expectations of forthcoming advancements …
The recent FDA approval marks a significant advancement, permitting the use of Ziihera in conjunction with Tevimbra® (tislelizumab-jsgr) and standard chemotherapy for adult patients afflicted with HER2-positive gastroesophageal adenocarcinoma (GEA). This multi-faceted treatment approach is designed to tackle a particularly aggressive form of cancer, …
System Placements Signal Confidence Amid Stock Decline
Please wait processing your request...